Every material Form 8-K NextCure, Inc. has filed with the SEC since September 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NextCure said its Chief Medical Officer, Dr. Udayan Guha, will be terminated effective October 31, 2026, in connection with the pending merger with Avere Therapeutics, Inc. He signed a severance agreement and release, and additional change-in-control severance is payable only if the merger closes.
Dr. Udayan Guha, Chief Medical Officer and a named executive officer, is terminated effective October 31, 2026.
The departure is tied to the pending merger of NextCure and Avere Therapeutics, Inc.
Severance follows his existing employment agreement; enhanced change-in-control severance applies only if the merger closes.
The filing does not state the dollar amount of severance.
NextCure filed a petition on September 14, 2026 in the Delaware Court of Chancery asking the court to validate its July 2025 reverse split and the shares issued in reliance on it. The company says a 2026 change to Delaware law creates uncertainty over whether a higher supermajority vote standard should have applied to the 2025 approval, which could affect its pending business combination with Avere Therapeutics and its capitalization. The filing describes the court hearing as the venue where the uncertainty will be addressed.
Petition filed September 14, 2026 under Section 205 of the Delaware General Corporation Law; the court ordered notice to stockholders on September 21, 2026.
The 2025 reverse split amendment received about 89.92% of votes cast and about 64.76% of outstanding shares, short of the 66 2/3% supermajority standard in the charter.
Hearing set for 3:00 p.m. Eastern Time on November 6, 2026 in Wilmington, Delaware.
Stockholders wishing to oppose the petition must file a written submission by October 27, 2026, or appear at the hearing.
NextCure amended its Beltsville, Maryland lease, vacated its remaining roughly 29,864 square feet effective August 31, 2026, and ended future rent obligations effective September 1, 2026. The company paid a one-time termination fee of about $0.8 million and forfeited a security deposit of about $39,000, which reduces its ongoing facility costs but involves a one-time cash charge.
Lease amendment dated August 28, 2026 covers about 29,864 rentable square feet at 8000 Virginia Manor Road, Beltsville, Maryland
Company vacated and surrendered the premises effective August 31, 2026
Future rent obligations terminated effective September 1, 2026
One-time termination fee of about $0.8 million paid and security deposit of about $39,000 forfeited
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NextCure, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →